Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | SCD | O00767 | 5/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21066432 | 0.89 | GSK3B (0.41) | GSK3BMLYCDSCDSLC8A1HRH3 | |
| SCHEMBL28312769 | 0.85 | GSK3B (0.39) | GSK3BMLYCDSCDSLC8A1HRH3 | |
| SCHEMBL22048060 | 0.81 | CRBN (0.41) | HRH3HCRTR2 | |
| SCHEMBL4025302 | 0.79 | PARP1 (0.41) | GSK3BMLYCDSCDHRH3 | |
| SCHEMBL745563 | 0.79 | GRM5 (0.43) | SLC8A1 | |
| SCHEMBL628266 | 0.77 | GSK3B (0.34) | GSK3BMLYCDSCDSLC8A1HRH3 | |
| SCHEMBL4781839 | 0.76 | GSK3B (0.36) | GSK3BMLYCDSCDSLC8A1HRH3 | |
| SCHEMBL29225034 | 0.73 | ESR2 (0.34) | ESR2 | |
| SCHEMBL12341805 | 0.73 | SMN1; SMN2 (0.37) | ESR2 | |
| SCHEMBL19984560 | 0.73 | ESR2 (0.32) | ESR2SLC8A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419417-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-25 | — | — | EP | disclosed |
| EP-2419417-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-25 | — | — | EP | disclosed |
| CN-102459225-B | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2 | JANSSEN PHARMACEUTICA NV | 2014-08-20 | — | — | CN | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| US-8269015-B2 | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| CN-102459225-A | 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2 | JANSSEN PHARMACEUTICA NV | 2012-05-16 | — | — | CN | disclosed |
| EP-2419417-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010121011-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010121011-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267688-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | GSK3B 3393/4885MLYCD 3440/4885ESR2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.